These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 12231368

  • 1. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil.
    Tedoriya T, Keogh AM, Kusano K, Savdie E, Hayward C, Spratt PM, Wilson M, Macdonald PS.
    J Heart Lung Transplant; 2002 Sep; 21(9):976-82. PubMed ID: 12231368
    [Abstract] [Full Text] [Related]

  • 2. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity.
    Al-Aly Z, Sachdeva A, Philoctete Ashley JM, Bastani B.
    Nephrology (Carlton); 2006 Apr; 11(2):151-5. PubMed ID: 16669979
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 2001 Apr 27; 71(8):1091-7. PubMed ID: 11374408
    [Abstract] [Full Text] [Related]

  • 4. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study.
    Sadek S, Medina J, Arias M, Sennesael J, Squifflet JP, Vogt B, Neo Int-05 Study group.
    Transplantation; 2002 Aug 27; 74(4):511-7. PubMed ID: 12352910
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E, Morelon E, Ducloux D, Bererhi L, Noël LH, Janin A, Bedrossian J, Puget S, Chalopin JM, Mihatsch M, Legendre C, Kreis H.
    Clin Transplant; 2000 Dec 27; 14(6):561-6. PubMed ID: 11127309
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
    Ducloux D, Motte G, Billerey C, Bresson-Vautrin C, Vautrin P, Rebibou JM, Saint-Hillier Y, Chalopin JM.
    Transpl Int; 2002 Sep 27; 15(8):387-92. PubMed ID: 12221456
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients.
    Hamour IM, Lyster HS, Burke MM, Rose ML, Banner NR.
    Transplantation; 2007 Mar 15; 83(5):570-6. PubMed ID: 17353776
    [Abstract] [Full Text] [Related]

  • 8. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
    Aleksic I, Baryalei M, Busch T, Pieske B, Schorn B, Strauch J, Sîrbu H, Dalichau H.
    Transplantation; 2000 Apr 27; 69(8):1586-90. PubMed ID: 10836367
    [Abstract] [Full Text] [Related]

  • 9. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction.
    Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, IJzermans JN, Weimar W.
    Transplantation; 2000 Jul 15; 70(1):143-8. PubMed ID: 10919591
    [Abstract] [Full Text] [Related]

  • 10. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP, Weinreich T, Ambühl PM, Schwarzkopf AK, Candinas D, Binswanger U.
    Nephrol Dial Transplant; 1999 Feb 15; 14(2):394-9. PubMed ID: 10069195
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.
    Transplantation; 2000 Mar 15; 69(5):834-41. PubMed ID: 10755536
    [Abstract] [Full Text] [Related]

  • 12. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine.
    Baryalei M, Zenker D, Pieske B, Tondo K, Dalichau H, Aleksic I.
    Transplant Proc; 2003 Jun 15; 35(4):1539-42. PubMed ID: 12826215
    [Abstract] [Full Text] [Related]

  • 13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181
    [Abstract] [Full Text] [Related]

  • 14. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM, Markezich AJ, Scandling JD, Dafoe DC, Alfrey EJ.
    J Surg Res; 1998 May 15; 76(2):131-6. PubMed ID: 9698512
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P, Cravedi P, Gotti E, Plati A, Marasà M, Sandrini S, Bossini N, Citterio F, Minetti E, Montanaro D, Sabadini E, Tardanico R, Martinetti D, Gaspari F, Villa A, Perna A, Peraro F, Remuzzi G.
    PLoS Med; 2021 Jun 15; 18(6):e1003668. PubMed ID: 34166370
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W.
    Liver Transpl; 2001 May 15; 7(5):442-50. PubMed ID: 11349266
    [Abstract] [Full Text] [Related]

  • 18. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
    Triemer HL, Pearson TC, Odom KL, Larsen CP.
    Clin Transplant; 2000 Aug 15; 14(4 Pt 2):413-20. PubMed ID: 10946781
    [Abstract] [Full Text] [Related]

  • 19. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
    Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW.
    J Am Soc Nephrol; 2002 Feb 15; 13(2):536-543. PubMed ID: 11805185
    [Abstract] [Full Text] [Related]

  • 20. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.
    Transpl Int; 2003 Nov 15; 16(11):820-7. PubMed ID: 12879230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.